[1] Simon S, Jon E, Trevor B, et al. Narative review; Aspirin resistance and ils cinical implications[J]. Ann Interm Med, 2005;142:370-380. [2] Tran H, Anand S, Hankey G, et al. Aspirin resistance[J].Thromb Res, 2007; 120:337-346. [3] Gum PA, Kottke Marchant K, Poggio ED. Profile and prevalenceof aspirin resistance in patienls with cardliovascular disease[J].Am J Carliol, 2001;88:230-235. [4] Valles J, Sanlos M, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an an-tithrombotic therapeutic modality: the effecl of low-dose is lessthan optimal in patients with vascular disease due to prothrom-botic effects of erythrocytes on platelet reactivity[J]. Circula-tion, 1998;97:350-355. [5] Marc K, Perry V. Why are some individuals resistant to the car-dioprotective effects of aspirin? Coud it be thromboxame A[J].Circulation, 2002; 105: 1650-1622. [6] John W, Jack H, Jeffrey I, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or car-diovascular death in patients al high risk for cardiovascular events[J]. Circulation, 2002; 105: 1620-1655. [7] Angiolillo D, Femnandez Ortiz A, Bernardo E, et al. Infuence of aspirin resistance on platelet funetion profiles in patients on long-term aspirin and clopidogrel after pereutaneous coronary. inter-vention[J]. Am J Cardiol, 2006;97:38-43. [8] 王春波,胡大一,史旭波,等.服用小剂量阿司匹林患者的阿司匹林抵抗[J].中国危重病急救医学2006;18:219-223. [9] Mirkhel A, Peyster E, Sundeen J, et al. Frequency of aspirin resistance in a commur hospital[J]. Am J Cardiol, 2006;98: 577-579. [10] Michelle O, Stephen D. Clopidogrel response variability and futun therapies[J]. Circulation, 2006;114:e600–e606. [11] Jneid H, Bhatt D, Corti R, et al. Aspirin and cloplogrel in acute corcmy syndromes: therapeutic insights from the CURE study[J]. Arch Intern Med, 2003; 163: 1145 1153. |